Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis
Davide Povero, Miloš Lazić, Christopher McBride, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 386, Iss. 2, pp. 242-258
Closed Access | Times Cited: 7

Showing 7 citing articles:

Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Yifan Liu, Renjie Pan, Yuzhen Ouyang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 29
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads
Srinivasa Reddy Bonam, Dylan Mastrippolito, Philippe Georgel, et al.
Trends in Pharmacological Sciences (2023) Vol. 45, Iss. 1, pp. 81-101
Closed Access | Times Cited: 13
Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency
Pamela J. Smolak, MyTrang Nguyen, Christine Diamond, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 388, Iss. 3, pp. 798-812
Open Access | Times Cited: 5
The role of pyroptosis in metabolism and metabolic disease
Zhuyuan Zheng, Shaojie Yang, Wanlin Dai, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116863-116863
Open Access | Times Cited: 4
The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity
Christopher D. Putnam, Lori Broderick, Hal M. Hoffman
Immunological Reviews (2023) Vol. 322, Iss. 1, pp. 259-282
Open Access | Times Cited: 10
Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework
John R. Doedens, Pamela J. Smolak, MyTrang Nguyen, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 5, pp. 1438-1456
Open Access | Times Cited: 1
Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation
Danting Mao, Guo Jian-wei, Kunli Yang, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 734, pp. 150424-150424
Closed Access | Times Cited: 1
Page 1

Scroll to top